Wegovy-maker Novo Nordisk to cut 9,000 jobs in restructuring

Core Viewpoint - Novo Nordisk is undergoing a significant restructuring, cutting 9,000 jobs (approximately 11.5% of its workforce) to save $1.26 billion annually amid increasing competition, particularly from US rival Eli Lilly [1][5]. Group 1: Restructuring Details - The company aims to simplify its organization, enhance decision-making speed, and reallocate resources towards growth opportunities in diabetes and obesity [1]. - Approximately 5,000 of the job cuts will occur in Denmark, where the company currently employs 78,400 people globally [3]. - Novo Nordisk will incur one-off restructuring costs of $1.4 billion in Q3, including impairment charges, but anticipates $156.9 million in savings in Q4 [4]. Group 2: Financial Outlook - The operating profit growth forecast for this year has been revised down to between 4% and 10%, from a previous estimate of 10% to 16%, primarily due to restructuring costs [5]. - The company, valued at $650 billion last year, is facing challenges as sales growth for its leading product, Wegovy, slows and market share declines, particularly in the US [5][7]. Group 3: Market Performance - Novo Nordisk's shares have dropped nearly 46% since the beginning of the year, reducing its market value to approximately $181 billion as of the latest close [9]. - The company has warned of slower growth this year, partly due to competition from copycat medicines based on Wegovy's ingredients [7].